Sgemaglutide in type 2 diabetes – is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

(2017) Lene Jensen et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

(2017) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

(2016) Michael Nauck et al.   DIABETES CARE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Are we waiting too long for the cardiovascular outcome trials with the glucagon-like peptide-1 receptor agonists?

(2015) Sheila A Doggrell   Expert Opinion On Drug Safety

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

(2015) Christoph Kapitza et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

(2015) Jesper Lau et al.   JOURNAL OF MEDICINAL CHEMISTRY

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

(2015) Marc A. Pfeffer et al.   NEW ENGLAND JOURNAL OF MEDICINE